Zeto Inc Advances Outpatient EEG Strategy With New System and Clinical Trial Sponsorships

Zeto Inc is the focus of this weekly summary covering notable developments in its neurodiagnostics business. The company is promoting its new Zeto New Wave neurodiagnostic system for outpatient EEG, designed to tackle long U.S. wait times and workflow disruptions tied to staffing shortages and complex clinical processes.

New Wave features full head coverage with 21 soft-tip, no-mess electrodes aligned with the standard 10–20 system and an all-in-one recording device. The platform also supports synchronized video, audio, and optional signals, positioning it as a comprehensive solution for clinics seeking to streamline EEG acquisition and monitoring.

CEO Florian Strelzyk, PhD, emphasized that neurologist feedback shaped the system’s design, with priorities including broader access to EEG, easing staffing pressures, and improving the patient experience. This focus on workflow efficiency and usability suggests Zeto aims to deepen penetration in outpatient neurology settings where scalable, easy-to-use tools can drive higher procedure throughput.

Zeto also advanced its 2026 Clinical Trial Sponsorship Program, announcing winners for EEG-focused projects across Australia, the U.K., and the U.S. Selected studies will explore applications in stroke monitoring, delirium assessment, and epilepsy treatment, reflecting a push to extend EEG use beyond traditional inpatient environments.

By backing these research teams, the company is seeking robust clinical data that could support regulatory, reimbursement, and hospital procurement decisions. Strong outcomes from these trials may enhance the clinical validation of Zeto’s technology, differentiate its EEG platform from competitors, and help open doors to commercialization partnerships with health systems and academic centers.

Collectively, the week’s announcements underscore a dual strategy of product innovation and evidence generation for Zeto Inc. The launch of New Wave targets immediate workflow and capacity needs in outpatient EEG, while the trial sponsorship program aims to build longer-term clinical credibility, supporting the company’s future growth prospects in the global neurodiagnostics market.